- #ASGCT26 dispatch: In vivo CAR-T is everywhereBOSTON — Greetings from Boston, where I’ve been on the ground covering the American Society of Gene & Cell Therapy’s annual meeting all week. It’s a crucial moment for the field. Genetic medi…Endpoints · 2mo ago↗ source
- Drugmakers have to go through rigorous tests to get a lower tariff rateLanding a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive…Endpoints · 2mo ago↗ source
- Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform. The San Diego and Shanghai biotech has raised $95 mil…